Pharmaids Pharmaceuticals Limited Stock Price Today (NSE: PHARMAID)
Fundamental Score
Pharmaids Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Pharmaids Pharmaceuticals Limited share price today is ₹34.50, down 2.82% on NSE/BSE as of 7 August 2026. Pharmaids Pharmaceuticals Limited (PHARMAID) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹119.13 (Cr). The 52-week high for PHARMAID share price is ₹68.00 and the 52-week low is ₹25.60. The company has a Return on Equity (ROE) of -26.51% and a debt-to-equity ratio of 0.49.
Pharmaids Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance
Pharmaids Pharmaceuticals Limited share price chart: -15.44% return over the past month. 52-week high ₹68.00, 52-week low ₹25.60.
Pharmaids Pharmaceuticals Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹36.20 | ₹36.20 | ₹34.00 | ₹34.50 | 10.34K (Cr) | |
| ₹33.14 | ₹36.04 | ₹33.05 | ₹35.50 | 54.16K (Cr) | |
| ₹31.94 | ₹33.90 | ₹30.17 | ₹32.20 | 3.71K (Cr) | |
| ₹33.44 | ₹33.44 | ₹31.50 | ₹32.51 | 7.64K (Cr) | |
| ₹33.98 | ₹33.98 | ₹31.05 | ₹31.67 | 9.70K (Cr) | |
| ₹31.00 | ₹31.88 | ₹29.55 | ₹31.00 | 1.88K (Cr) | |
| ₹29.51 | ₹31.79 | ₹29.50 | ₹30.78 | 3.59K (Cr) | |
| ₹31.90 | ₹31.90 | ₹29.66 | ₹30.30 | 2.21K (Cr) | |
| ₹31.10 | ₹31.85 | ₹29.53 | ₹30.02 | 1.58K (Cr) | |
| ₹31.40 | ₹31.85 | ₹30.05 | ₹30.49 | 3.72K (Cr) |
Pharmaids Pharmaceuticals Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹33.98 | ₹36.20 | ₹30.17 | ₹34.50 | +1.53% | |
| ₹41.90 | ₹41.90 | ₹29.12 | ₹31.00 | -26.01% | |
| ₹30.90 | ₹41.25 | ₹25.60 | ₹38.97 | +26.12% | |
| ₹30.26 | ₹33.80 | ₹27.26 | ₹30.34 | +0.26% | |
| ₹27.90 | ₹35.00 | ₹27.90 | ₹29.67 | +6.34% | |
| ₹31.89 | ₹39.30 | ₹27.10 | ₹27.67 | -13.23% | |
| ₹40.60 | ₹44.00 | ₹30.00 | ₹31.44 | -22.56% | |
| ₹47.66 | ₹50.90 | ₹40.99 | ₹41.53 | -12.86% | |
| ₹46.90 | ₹53.90 | ₹43.30 | ₹47.66 | +1.62% | |
| ₹48.65 | ₹52.97 | ₹43.05 | ₹45.98 | -5.49% | |
| ₹58.01 | ₹60.79 | ₹42.00 | ₹49.51 | -14.65% | |
| ₹62.89 | ₹66.00 | ₹53.75 | ₹59.46 | -5.45% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Pharmaids Pharmaceuticals Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Pharmaids Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PHARMAID across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (56.88%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (50.52%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (-26.51%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-18.52%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-58.01%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Weak Interest Coverage (-4.38x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-54.48 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Pharmaids Pharmaceuticals Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Pharmaids Pharmaceuticals Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Pharmaids Pharmaceuticals LimitedPharmaids Pharm...Selected✓ PHARMAID • 524572 | 18/100 | ₹34.50₹35 | ₹119.13₹119.13 | — — | -26.51%Poor -26.51% Poor | -18.52%Poor -18.52% Poor | 0.49Excellent 0.5 Excellent | — — | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Pharmaids Pharmaceuticals Limited Quarterly Performance
Latest quarterly metrics for PHARMAID — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
50.52%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
56.88%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Pharmaids Pharmaceuticals Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for PHARMAID — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Pharmaids Pharmaceuticals Limited Financial Statements
Annual income statement, balance sheet and cash flow for Pharmaids Pharmaceuticals Limited (PHARMAID) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Pharmaids Pharmaceuticals Limited
About PHARMAID (Pharmaids Pharmaceuticals Limited)
Pharmaids Pharmaceuticals Limited is a dynamic and innovative force within the global pharmaceutical landscape, dedicated to pioneering advancements in healthcare through cutting-e...dge research, development, and manufacturing. With an unwavering commitment to improving patient lives, Pharmaids leverages its state-of-the-art facilities and a team of highly skilled scientists and engineers to create a diverse portfolio of high-quality pharmaceutical products. The company's core values revolve around integrity, quality, and innovation, driving its relentless pursuit of excellence in every aspect of its operations. Pharmaids's strong emphasis on research and development allows it to stay at the forefront of emerging therapeutic areas and deliver innovative solutions to unmet medical needs. At the heart of Pharmaids' operations lies a dedication to meeting the evolving needs of its customers and partners. The company boasts a comprehensive suite of services, encompassing custom synthesis, process development, and large-scale manufacturing. Pharmaids' commitment to quality is evident in its adherence to stringent regulatory standards and its implementation of robust quality control measures throughout the manufacturing process. With a global reach, Pharmaids serves a diverse clientele, including leading pharmaceutical companies, research institutions, and healthcare providers. Its collaborative approach and customer-centric focus ensure that its partners receive tailored solutions that meet their specific requirements, driving mutual success and long-term partnerships. Pharmaids Pharmaceuticals Limited distinguishes itself through its unwavering focus on sustainability and social responsibility. The company is committed to minimizing its environmental impact through the implementation of eco-friendly practices and the responsible use of resources. Pharmaids also actively engages in community outreach programs, supporting initiatives that promote health and education in underserved populations. By integrating sustainability and social responsibility into its core business practices, Pharmaids strives to create a positive impact on both the environment and the communities in which it operates. This commitment reflects the company's belief that business success and social progress are intrinsically linked.
Company Details
Key Leadership
Latest News
PHARMAID Share Price: Frequently Asked Questions
What is the current share price of Pharmaids Pharmaceuticals Limited?
Pharmaids Pharmaceuticals Limited (PHARMAID) trades at ₹34.50 on NSE and BSE. Market cap ₹119.13 (Cr). Educational data only.
What is the P/E ratio of Pharmaids Pharmaceuticals Limited?
Pharmaids Pharmaceuticals Limited has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Pharmaids Pharmaceuticals Limited?
Pharmaids Pharmaceuticals Limited has a Bull Run score of 18/100 based on 25+ financial parameters.
Does Pharmaids Pharmaceuticals Limited pay dividends?
Pharmaids Pharmaceuticals Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Pharmaids Pharmaceuticals Limited?
Pharmaids Pharmaceuticals Limited has ROE of -26.51%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Pharmaids Pharmaceuticals Limited?
Pharmaids Pharmaceuticals Limited has debt-to-equity of 0.49.
Is Pharmaids Pharmaceuticals Limited a good investment?
Bull Run gives Pharmaids Pharmaceuticals Limited a score of 18/100. This is not investment advice — consult a SEBI-registered advisor.